Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens.

Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.

Key Stats

• Today's Range: $18.57 to $20.28
• 50-Day Range: $10.64 to $20.26
• 52-Week Range: $5.14 to $29.46
• Volume: 434,988 shs
• Average Volume: 369,625 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Buy

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 672nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Upstream Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

Price to Book Value per Share Ratio

Upstream Bio has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UPB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for UPB.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.16

News Sentiment

Upstream Bio has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Upstream Bio this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

UPB Stock Analysis - Frequently Asked Questions

How have UPB shares performed this year?

Upstream Bio's stock was trading at $16.44 on January 1st, 2025. Since then, UPB shares have increased by 17.8% and is now trading at $19.36.

How were Upstream Bio's earnings last quarter?

Upstream Bio, Inc. (NASDAQ:UPB) issued its earnings results on Wednesday, August, 6th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.13. The firm earned $0.94 million during the quarter, compared to analyst estimates of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative trailing twelve-month return on equity of 35.90%.

When did Upstream Bio IPO?

Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Who are Upstream Bio's major shareholders?

Upstream Bio's top institutional investors include Bain Capital Life Sciences Investors LLC (4.53%), Norges Bank (1.80%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.54%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends.

How do I buy shares of Upstream Bio?

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Upstream Bio: $56.50
• High Price Target: $75.00
• Low Price Target: $38.00
• Potential Upside/Downside: +185.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.81 million
• Net Margins: -3,836.58%
• Pretax Margin: -3,836.58%
• Return on Equity: -35.90%
• Return on Assets: -26.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 38.27
• Quick Ratio: 38.27

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 449.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.58 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 53,910,000
• Free Float: 46,599,000
• Market Cap: $1.07 billion
• Optionable: N/A
• Beta: N/A